As US President, Donald Trump’s actions decimated federal research into cancer and other diseases, targeting staff and freezing billions in funding, as well as cutting programmes.
The grant cancellations appear to be part of the administration’s anti-diversity, anti-trans and anti-vaccine agendas, as Trump officials maintain a list of “flagged” keywords that trigger programme reviews.
So far, coverage of Trump’s disruption to cancer research has focused on the damage to projects and people.
Now, the confusion caused by Trump’s actions is making it harder for researchers to coordinate new projects and partnerships.
This will impact achievements in cancer and prevent breakthroughs.
